Hagens Berman represents whistleblowers in cases alleging pharmaceutical fraud, including off-label marketing, unlawful billing methods and other schemes that defraud the taxpayer by overcharging government programs for life-saving drugs.
Under the False Claims Act, a federal statute, whistleblowers that expose fraud committed against the government are entitled to between 15 and 30 percent of funds the government recovers from defendants.
If you have information on fraud committed against the government, you may qualify as a whistleblower, and you are encouraged to contact an attorney to discuss your rights.
Hagens Berman has taken on the largest pharmaceutical companies and wholesalers and won billions of dollars in recoveries for governments and consumers who overpaid for life-saving drugs.
You can contact Hagens Berman by clicking here, or by calling (206) 623-7292.
Here are some examples of our work:
McKesson Drug Price Inflation Litigation: Hagens Berman represented a class of cities, counties and municipalities against McKesson Corp. alleging that the pharmaceutical giant fraudulently inflated the price of over 400 brand-name prescription drugs. Total recoveries in the cases approach $1 billion.
Zyprexa Marketing and Sales Practices Litigation – Hagens Berman served as outside counsel to Connecticut Attorney General Richard Blumenthal in litigation alleging that Lilly engaged in unlawful offlabel promotion of the atypical antipsychotic Zyprexa. The litigation concluded with a $25 million settlement that Hagens Berman negotiated.
Neurontin Third-Party Payor Litigation – Hagens Berman served as co-lead trial counsel in this case alleging that Pfizer fraudulently and unlawfully promoted the drug Neurontin for uses unapproved by the FDA. A jury returned a $47 million verdict in favor of plaintiffs.